A Clinical Study of Intravenous T3011 Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors Read more about A Clinical Study of Intravenous T3011 Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Read more about Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
National Cancer Institute "Cancer Moonshot Biobank" Read more about National Cancer Institute "Cancer Moonshot Biobank"
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET Read more about Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer Read more about TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Carbon Ion RT for Locally Advanced Pancreatic Cancer Read more about Carbon Ion RT for Locally Advanced Pancreatic Cancer
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Read more about Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Nutrition and Pharmacological Algorithm for Oncology Patients Study Read more about Nutrition and Pharmacological Algorithm for Oncology Patients Study
A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors Read more about A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors